XenoPort's (XNPT) XP-829 Efficacy 'Looks Good' - RBC Capital

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. PTC
2. NVDA
3. PCVX
4. META
5. MSFT
6. SPY
7. GOOGL
8. GMAB
9. USO
10. AMD

Go back to XenoPort's (XNPT) XP-829 Efficacy 'Looks Good' - RBC Capital

XenoPort Announces Positive Phase 2 Study Results for XP23829 as a Potential Treatment for Patients with Psoriasis

September 15, 2015 6:30 AM EDT

Efficacy observed with both 800 mg once-daily and 400 mg twice-daily XP23829 dosing XP23829 safe and generally well-tolerated with low incidence of flushing similar to placebo Low incidence/severity of lymphopenia seen with XP23829 First clinical demonstration of efficacy of a MMF prodrug other than DMF

SANTA CLARA, Calif.--(BUSINESS WIRE)-- XenoPort, Inc. (Nasdaq: XNPT) announced today positive preliminary top-line results from its Phase 2 clinical trial of XP23829 as a potential... More